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 Abstract 
Rationale: There is evidence that the serotonin (5-HT) deficits and related 
cognitive and mood impairments caused by +/-3,4-
methylenedioxymethamphetamine (MDMA) may be mediated by 
neuroadaptations of the 5-HT1A autoreceptor. 
Objectives: The increase in sensitivity of the 5-HT1A autoreceptor caused by high-
dose, repeated MDMA treatment was assessed neurochemically, by measuring 5-
HTP accumulation, and physiologically, via changes in body temperature. 
Methods: Experiment 1 confirmed the effects of 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT) (0, 0.025, 0.05, 0.1 mg/kg s.c.) on 5-
hydroxytryptophan (5-HTP) accumulation following 3-hydroxybenzylhydrazine 
dihydrochloride (NSD-1015) administration as a valid measure of 5-HT synthesis 
and hence 5-HT1A autoreceptor sensitivity in rats. Experiment 2 performed these 
procedures in additional animals, with half receiving MDMA (4x 10 mg/kg i.p. at 
2 hour intervals) two weeks before testing. Body temperature changes due to the 
8-OH-DPAT hypothermic response were tested using a rectal probe. Experiment 
2b repeated the procedures in additional groups with lower doses of 8-OH-DPAT 
(0.0125 and 0.00625 mg/kg s.c.). 
Results: No significant changes in 5-HTP accumulation levels or changes in the 
hypothermic response to 8-OH-DPAT were found between MDMA pretreated 
rats and controls in Experiments 2 and 2b. Moreover, there was no substantial 
evidence of expected 5-HT deficits due to high-dose MDMA treatment. 
Conclusion: The results do not indicate an increase in sensitivity of the 5-HT1A 
autoreceptor, and hence the original hypothesis is not supported. However, there 
were a number of methodological issues, as indicated by the lack of MDMA-
induced 5-HT deficits, which prevent a firm conclusion from being drawn. Future 
research is outlined to overcome these issues. 
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Introduction 
Substance abuse and dependence are serious global problems with many 
social and economic impacts. A positive step in recent years has been the return of 
health to the core of drug policy. Substance dependence is now seen as a treatable 
condition, with new evidence-based methods of helping those affected (United 
Nations Office on Drugs and Crime (UNODC), 2010). One grouping of abused 
substances are amphetamine-type stimulants, which includes amphetamine, 
methamphetamine, and 3,4-Methylenedioxymethamphetamine (MDMA) along 
with its analogues. MDMA, or 'ecstasy' as it is known on the street, rose out of a 
popularity surge in the United States and parts of Europe in the 1980s to become 
the global phenomenon it is today (UNODC). 
The ring-substituted amphetamine derivative was first synthesised by the 
German pharmaceutical company Merck in 1912 as an intermediate compound in 
the synthesis of other drugs (Benzenhöfer & Passie, 2006; Freudenmann, Oxler, 
& Bernschneider-Reif, 2006). However, MDMA remained largely on the shelf 
until 1976 when it was re-synthesised by the experimental psychopharmacologist 
Alexander Shulgin (Shulgin & Nichols, 1978; McDowell & Kleber, 1994). After 
it was first informally distributed by Shulgin and others for experimentation and 
as a possible tool in psychotherapy, MDMA soon crossed over into wider public 
use, where it was associated with early 1980s dance and rave scenes in the US 
(Gowing, Henry-Hedwards, Irvine, & Ali, 2001). The increasing popularity of 
MDMA, together with growing evidence of its neurotoxicity in laboratory animals, 
led to its being scheduled in the US, UK and other countries as a Class 1 illicit 
drug in the early 1980s (McDowell & Kleber, 1994; Nutt, 2008). 
MDMA has distinct pharmacological effects from other stimulants in that it 
produces a unique sense of warmth and empathy for others (Greer & Tolbert, 
1998). Because of this unique combination of stimulant and pro-social effect, 
some researchers argue that it represents a new class of drugs, and declare 
MDMA as the archetypical 'entactogen' (Nichols & Oberlender, 1990). These 
aspects of MDMA have also led some researchers and therapists to believe 
MDMA may be a useful tool in psychotherapy. Indeed, before MDMA was 
classified as a controlled substance, a number of psychiatrists used MDMA as an 
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adjunct to psychotherapy, reporting that MDMA could decrease feelings of fear 
and raise empathy in patients while maintaining a clear-headed, alert state of 
consciousness (Greer & Tolbert, 1998). Interest in MDMA's use in this respect 
has recently been rekindled with a clinical trial for MDMA-assisted 
psychotherapy in subjects with posttraumatic stress disorder being published 
(Mithoefer, Wagner, Mithoefer, Jerome, & Doblin, 2010). 
MDMA Epidemiology and Patterns of Use 
Trends in global MDMA consumption, manufacture and trafficking are 
dynamic, becoming more prevalent in new locations around the world (19 
countries recently reported an increase) while remaining stable or declining in 
others (UNODC, 2010). In the US, following a spike in MDMA use in the early 
2000s, 2008 survey results show a maintenance of the lifetime prevalence rate 
among 19 to 28 year olds (13.1%) that is comparable to cocaine (14.8%) and 
hallucinogens (14.8%) (Johnston, O’Malley, Bachman, & Schulenberg, 2010). 
The British Crime Survey (2010) reveals a similar trend, in which MDMA use in 
England and Wales has remained fairly stable over recent years, with an 
approximate annual consumption of 60 million 'ecstasy' tablets (Singleton, 
Murray, & Tinsley, 2006). Locations where MDMA use is increasing include 
many parts of the developing world and Asia (UNODC). Moreover, the Oceania 
region has one of the highest annual, and rising prevalence rates of MDMA use in 
the world (UNODC). In New Zealand for example, a survey found that the 
population prevalence of MDMA consumption increased from 5.2% in 2004 to 
7.5% in 2006 (Wilkins, Griffiths, & Sweetsur, 2009). 
Research also shows that users increase their MDMA dose with experience, 
and recent studies show trends of higher doses of MDMA and use of the drug in 
more diverse situations. For instance, Fox, Parrott and Turner (2001) compared 
three MDMA user subgroups divided by MDMA experience: low users (1 - 99 
tablets in lifetime), medium users (100 - 499 tablets) and high users (500+ tablets). 
As MDMA experience increased, there was a parallel increase in the number of 
tablets normally consumed per occasion, together with a greater maximum 
number of tablets taken on any one occasion. Additionally, in a recent survey of 
drug use by dance club attendees, Measham and Moore (2009) found a trend 
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towards increased dosage of MDMA. Several studies have also found a trend 
towards MDMA use outside of the electronic music scene, in increasingly diverse 
populations and situations (Wilkins, Bhatta, Pledger, & Casswell, 2003; Wilkins, 
Sweetsur, & Casswell, 2006). 
As likely consequences of increases in prevalence and dosing, MDMA 
abuse and dependence are serious issues. Cottler, Leung and Abdallah (2009) 
interviewed 593 MDMA users across three different cities and found that 15% 
and 59% met DSM-IV criteria for MDMA abuse and dependence respectively. In 
the assessment, ‘continued use despite knowledge of physical/psychological 
problems’ (87%) and ‘withdrawal’ (68%) were the two most prevalent 
dependence criteria. An earlier study by Cottler (2009) found similar results, with 
43% of MDMA users meeting criteria for dependence and 34% for abuse. 
Furthermore, in a 2003 survey, 59% of participants reported tolerance to the 
effects of MDMA (Verheyden, Henry, & Curran, 2003) and it is common for 
users to report a reduction in the positive effects of MDMA within the first few 
occasions of use (Peroutka, Newman, & Harris, 1988; Topp, Hando, Dillon, 
Roche, & Solowij, 1999; Parrott, 2001; Scholey et al., 2004). As a result of 
tolerance, which is an important criterion for substance dependence, drug intake is 
often escalated through methods such as increases in dose to sustain a high, and 
changing administration routes (Fox et al., 2001; Verheyden et al., 2003; Carlson, 
Falck, McCaughan, & Siegal, 2004; Scholey et al., 2004). The research described 
here illustrates how MDMA use is maintained at high rates or is increasing around 
the world, and is coupled with a trend of increases in dose and substantial 
evidence of clinical abuse and dependence. 
Adverse Acute and Long-Term Effects of MDMA 
Accumulating evidence indicates that MDMA can cause serious acute and 
long-term health concerns. Acute adverse effects of MDMA intoxication in 
humans include cardiac arrhythmias, hypertension, hyperthermia, serotonin 
syndrome, hyponatremia, liver problems, seizures, coma, and, in rare cases, death 
(Schifano, 2004). In rats, with which a large proportion of substance abuse 
research occurs, MDMA produces a range of acute behavioural responses 
including hyperkinesis, increased heart rate, and symptoms of serotonin syndrome 
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such as forepaw treading, flattened body posture, and head weaving (Gold, Koob, 
& Geyer, 1988; Spanos & Yamamoto, 1989; O’Cain, Hletko, Ogden, & Varner, 
2000). MDMA has also been found to produce disruptions in thermoregulation in 
rats, termed poikilothermia, which leads to hypothermia in cold environments and 
hyperthermia in mild and hot environments (Nash, Meltzer, & Gudelsky, 1988; 
Dafters, 1995; Dafters & Lynch, 1998). 
Long-term MDMA abuse is associated with persistent cognitive 
impairments and mood disturbances, and increased risk of psychological disorders 
(Morgan, 2000; Parrott et al., 2002). In MDMA users, an array of 
neuropsychological tests have revealed that working, short-term and long-term 
memory, and executive functioning, were all significantly impaired in regular and 
heavy users (McCann, Mertl, Eligulashvili, & Ricaurte, 1999; Reneman, Booij, 
Schmand, van den Brink, & Gunning, 2000; Fox et al., 2001; McCardle, Luebbers, 
Carter, Croft, & Stough, 2004). Additionally, more extensive incidents of 
emotional disorders, such as depression and anxiety disorders, have been found in 
heavy MDMA users (Morgan, 2000; Fox et al., 2001; Parrott et al., 2002).  
It is important to note that there are a range of issues related to human drug 
abuse research that limit the validity and reliability of MDMA research in humans. 
Such issues include an inability to accurately ascertain drug taking history due to 
significant polydrug use (Scholey et al., 2004), variance in the actual MDMA 
content of so-called ecstasy tablets (Parrott, 2004), reliance on memory to recall 
past drug taking events, and self-report reliability issues due to MDMA's illegal 
status. However, notwithstanding these limitations, the research still paints a clear 
picture of long-term impairments associated with MDMA abuse in humans. 
The long-term effects of MDMA have also been extensively studied in 
laboratory animals, such as the rat. These studies allow much greater experimental 
control and scope in not being limited by the constraints associated with human 
research. The animal literature supports the human research in finding that 
MDMA exposure is associated with persistent impairments in cognitive 
functioning in both rats and nonhuman primates, including impaired spatial 
memory, executive functioning, and attention (McCann et al., 1999; Williams et 
al., 2003; Sprague, Preston, Leifheit, & Woodside, 2003; Vorhees, Reed, Skelton, 
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& Williams, 2004; Cohen et al., 2005). For example, Sprague et al. (2003) tested 
MDMA pretreated (2x 20 mg/kg s.c., given 12 h apart) rats in the Morris water 
maze and found significant memory impairments. Further impairments were 
found by Marston, Reid, Lawrence, Olverman and Butcher (1999) in a delayed 
non-match to performance procedure, where MDMA pretreated animals exhibited 
short-term memory impairments.  
There is also evidence that MDMA can have persistent anxiogenic effects in 
rats as shown through behavioural measures of anxiety, such as social interaction 
and emergence tests (Morley, Gallate, Hunt, Mallet, & McGregor, 2001; Gurtman, 
Morley, Li, Hunt, & McGregor, 2002; McGregor et al., 2003b; Sumnall, O’Shea, 
Marsden, & Cole, 2004). These tests involve recording the animal’s behaviour in 
potentially anxiety-inducing scenarios, for instance emerging from a home cage 
into an open arena.  Significant increases in anxiety-like behaviour in an elevated 
plus-maze have been reported in rats pretreated with MDMA (4x 5 mg/kg i.p. for 
2 days) (Gurtman et al.) and significantly attenuated social interaction measures in 
rats have also been reported weeks after MDMA pretreatment (7.5 mg/kg i.p., 
twice daily for 3 days) (Fone et al., 2002). Furthermore, in the forced swim test of 
depression-like behaviour, MDMA pretreated rats (4x 5mg/kg i.p. for 2 days) 
exhibited reduced escape attempts and increased immobility (Mcgregor et al., 
2003a).  
Conversely, some studies have found no significant long-term impairments 
in learning and memory tasks in rats, despite observing marked physiological 
brain deficits caused by MDMA (Robinson, Castañeda, & Whishaw, 1993; Seiden 
et al., 1993; Byrne, Baker, & Poling, 2000). The different results of these studies 
could be due to the type of learning and memory task employed, differing MDMA 
administration procedures, and the tests used not being sensitive enough to detect 
the impairments produced by MDMA. Despite these complexities, given the 
potential of MDMA to cause persistent impairments in cognition and mood, it is 
important to investigate further the mechanisms underlying these impairments and 
possibilities for their reversal. 
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MDMA Pharmacology 
Both (+) and (−) isomers of MDMA are bioactive (Johnson, Hoffman, & 
Nichols, 1986; Schmidt, 1987) and ecstasy tablets ingested by humans contain a 
racemic mixture of both stereoisomers. Upon systemic administration, N-
demethylation of MDMA occurs via first-pass metabolism to yield 3,4-
methylene-dioxyamphetamine (MDA) (de la Torre et al., 2004). MDMA and 
MDA act to increase the release of the monoamine neurotransmitters serotonin (5-
HT), dopamine (DA), norepinephrine (NE), and histamine; together with 
acetylcholine (Nichols, Lloyd, Hoffman, Nichols, & Yim, 1982; Johnson et al., 
1986; McDowell & Kleber, 1994). MDMA and MDA bind to cell plasma 
membrane monoamine transporters and are translocated into the cytoplasm, where 
they are known to act to increase monoamine levels through two mechanisms: 
reversal of the normal transporter function to release neurotransmitter molecules 
through their concentration gradients, and an increase of cytoplasmic 
neurotransmitter concentrations through disruption of vesicular membrane 
transporters (Schuldiner, Steiner-Mordoch, Yelin, Wall, & Rudnick, 1993; Green, 
Cross, & Goodwin, 1995; Rothman & Baumann, 2002). MDMA also inhibits the 
catabolic enzyme monoamine oxidase (MAO) (Leonardi & Azmitia, 1994), 
thereby reducing the metabolism of monoamine neurotransmitters and further 
contributing to their increased activity at the synapse. 
Of the monoamines, MDMA preferentially releases 5-HT (Yamamoto, Nash, 
& Gudelsky, 1995; Kankaanpää, Meririnne, Lillsunde, & Seppälä, 1998), with 
potency, for example, approximately ten times that of methamphetamine (White, 
Obradovic, Imel, & Wheaton, 1996). For instance, it has been found that rapidly 
following systemic administration of 2.5 mg/kg MDMA there is an approximate 
increase of 600% in extracellular serotonin in the frontal cortex, and a 2,600% 
increase with 20 mg/kg MDMA (Gudelsky & Nash, 1996). The increases in 
extracellular 5-HT following MDMA administration are predominantly seen in 
the striatum (Gough, Ali, Slikker, & Holson, 1991; Sabol & Seiden, 1998), the 
frontal cortex (Gartside, McQuade, & Sharp, 1997), the nucleus accumbens 
(Kankaanpää et al., 1998), the substantia nigra (Yamamoto et al., 1995), and the 
hippocampus (Colado & Green, 1994; Mechan et al., 2002). These areas are 
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terminal fields projected to by the 5-HT neurons of the raphe nuclei in the 
midbrain (Segal, 1975; Sprouse & Aghajanian, 1988). The 5-HT cell bodies of the 
raphe nuclei play a critical role in regulating the serotonin system and mediating 
the effects of MDMA on the brain. To explain these effects further, the 
fundamentals of this neurotransmitter system and its receptors need to be 
introduced.  
The Serotonin System 
5-HT is a monoamine neurotransmitter in the CNS of humans and other 
animals. 5-HT cell bodies are situated in the nine raphe nuclei, located along the 
rostrocaudal midline of the brain stem (Dahlström & Fuxe, 1964). Serotonergic 
neurons derive mainly from two raphe nuclei: the dorsal (DRN) and median 
(MRN) nuclei (Conrad, Leonard, & Pfaff, 1974). Neurons in these nuclei project 
predominately to different serotonin terminal regions. The 5-HT pathways to the 
frontal cortex (FC) and striatum (St) mainly originate from 5-HT neurons located 
in the DRN, while the 5-HT pathways to the hippocampus (Hip) emanate from 
both the DRN and MRN, although primarily the MRN (Miller, Richardson, 
Fibiger, & McLennan, 1975; Azmitia & Segal, 1978; Jacobs, Foote, & Bloom, 
1978; Imai, Steindler, & Kitai, 1986). 
Serotonin is synthesised in a metabolic pathway beginning with the essential 
amino acid L-tryptophan being converted to 5-hydroxy-L-tryptophan (5-HTP) in 
the rate-limiting step by the enzyme tryptophan hydroxylase (TPH) (Fernstrom & 
Wurtman, 1971). This important enzyme is now known to exist in two different 
isoforms encoded by two different genes: the original TPH, referred to now as 
TPH1, and the newly discovered isoform, identified as TPH2 (Walther & Bader, 
2003). The two isoforms also differ in their anatomical distribution, with TPH2 
being exclusively expressed in the brain and TPH1 primarily in the periphery (Zill 
et al., 2007). The majority of TPH2 mRNA is synthesised in the raphe nuclei 
(Patel, Pontrello, & Burke, 2004; Zill et al., 2007) and is thought to be transported 
to cortical and subcortical brain regions through axons (Bonkale & Austin, 2008). 
In the next step of the metabolic pathway, 5-HTP is converted to 5-HT by 
aromatic L-amino acid decarboxylase. 5-HT is metabolised by MAO, producing 
the main metabolite 5-Hydroxyindoleacetic acid (5-HIAA). 
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There are at least 16 structurally and pharmacologically distinct mammalian 
5-HT receptor subtypes, each belonging to one of seven families based on their 
primary signalling mechanisms: 5-HT1 to 5-HT7 (Barnes & Sharp, 1999; Polter 
& Li, 2010). Of particular importance to MDMA's effects on the brain, and a 
member of the 5-HT1 family, the 5-HT1A receptor was the first 5-HT receptor to 
be fully sequenced and is one of the best characterised due to early anxiolytic and 
antidepressant findings. Morphologically, the 5-HT1A receptor consists of a single 
polypeptide chain with seven putative transmembrane domains (Hoyer et al., 
1994). Findings from electrophysiological, ligand binding, in situ hybridization 
and immunocytochemical studies reveal that the 5-HT1A receptor exists as an 
inhibitory somatodendritic autoreceptor and as a postsynaptic heteroreceptor 
(Vergé et al., 1986; Sprouse & Aghajanian, 1987; Sprouse & Aghajanian, 1988; 
Sotelo, Cholley, El Mestikawy, Gozlan, & Hamon, 1990; Chalmers & Watson, 
1991). The 5-HT1A receptor is located on 5-HT neurons and dendrites in the raphe 
nuclei (autoreceptors) and on non-5-HT neurons in many other subcortical and 
cortical areas that serotonin neurons project to (heteroreceptors). High 5-HT1A 
receptor binding density is found in the DRN and MRN of the raphe nuclei, in the 
hippocampus, the amygdala and in limbic cortical areas. Medium binding density 
is found in the olfactory bulb, the thalamus, hypothalamus, and the neocortex. 
Low or no levels are detected in the basal ganglia and cerebellum (Hall et al., 
1985; Vergé et al., 1986; Albert, Zhou, Van Tol, Bunzow, & Civelli, 1990; 
Pompeiano, Palacios, & Mengod, 1992; Kia, Brisorgueil, Hamon, Calas, & Vergé, 
1996; Kia et al., 1996; Maeda et al., 2001). In the neocortex the 5-HT1A 
heteroreceptor is expressed mainly on pyramidal glutamatergic neurons, and in 
pyramidal and granular neurons of the hippocampus (Pompeiano et al., 1992). 
Heteroreceptors are also found in the raphe nuclei, although in low density in 
comparison to 5-HT1A autoreceptors in the raphe (Gozlan, El Mestikawy, Pichat, 
Glowinski, & Hamon, 1983; Verge et al., 1985; Riad et al., 2000).  
Stimulation of 5-HT1A receptors inhibits nerve cell firing via membrane 
hyperpolarisation consequent to activation of a pertussis toxin-sensitive G protein-
coupled K+ conductance (Andrade, Malenka, & Nicoll, 1986; De Vivo & Maayani, 
1986; Innis & Aghajanian, 1987; Hamon et al., 1988; Innis, Nestler, & 
Aghajanian, 1988; Chamberlain et al., 1993; Albert, Lembo, Storring, Charest, & 
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Saucier, 1996; Clarke, Yocca, & Maayani, 1996). In addition, there are a number 
of differences in other signal transduction cascades between the 5-HT1A 
autoreceptors and hetereoreceptors. The 5-HT1A hetereoreceptor, but not the 
autoreceptor (Clarke et al., 1996; Johnson, Fiorella, Winter, & Rabin, 1997), 
couples negatively via Gi/Go proteins to adenylate cyclase. In this case, 
stimulation inhibits adenylate cyclase, thereby depressing cyclic adenosine 
monophosphate (cAMP), and in turn, decreasing the activity of protein kinase A 
(PKA). This cascade has the effect of inhibiting PKA phosphorylation of TPH - 
the enzyme responsible for catalysing the rate-limiting step in serotonin synthesis. 
Interestingly however, 5-HT1A receptor agonists have been reported to inhibit 
adenylate cyclase activity, supposedly via 5-HT1A autoreceptors, in raphe from 
postmortem human brain (Palego et al., 1999; Marazziti et al., 2002). Furthermore, 
5-HT1A autoreceptors alone reduce a Ca2+ conductance, which contributes to the 
negative effects of 5-HT1A autoreceptor stimulation on cell firing of 5-HT neurons 
(Andrade & Nicoll, 1987; Sprouse & Aghajanian, 1987; Ropert, 1988; Sprouse & 
Aghajanian, 1988). Therefore, the two subtypes of 5-HT1A receptors have 
functional differences depending on their neuronal location. 
Ligands for the 5-HT1A receptor have been developed to identify the 
receptor in the brain and study its functions. As an exemplar, the selective 5-HT1A 
receptor agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) has been 
extensively used to investigate the functional status of the 5-HT1A receptor (Hjorth, 
Carlsson, Lindberg, & Sanchez, 1982; Hjorth, 1985; Hillegaart, 1991). The 
selectivity of 8-OH-DPAT is confirmed by the complete inhibition of its effects 
by selective 5-HT1A antagonists, such as WAY100635 and the older and less 
selective WAY100135 (Gozlan et al., 1983; Adell, Carceller, & Artigas, 1993; 
Bosker, Donker, Klompmakers, Kurata, & Westenberg, 1994; Forster et al., 1995; 
Davidson & Stamford, 1995). Moreover, it is evident that low doses of 8-OH-
DPAT preferentially target the 5-HT1A autoreceptor over the heteroreceptor 
(Hjorth & Magnusson, 1988; Hoyer, Hannon, & Martin, 2002). Selective 5-HT1A 
agonists, including 8-OH-DPAT, have been shown to be more potent when 
applied onto 5-HT neurons, and hence activate autoreceptors, than when they are 
applied onto non-5-HT neurons where they activate heteroreceptors (Blier, De 
Montigny, & Chaput, 1987; Blier & De Montigny, 1990). A possible molecular 
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basis for the autoreceptor selectivity of 8-OH-DPAT is the large 5-HT1A receptor 
reserve for 5-HT1A agonists found in the raphe nuclei, in comparison to cortical 
and limbic areas (Meller, Goldstein, & Bohmaker, 1990; Cox, Meller, & 
Waszczak, 1993; Jolas et al., 1995). It is also possible to describe receptors such 
as the 5-HT1A as existing in several conformational states, including 'high-affinity' 
and 'low-affinity' states, with agonists, such as 8-OH-DPAT, binding 
preferentially to certain states (Samama, Cotecchia, Costa, & Lefkowitz, 1993). In 
this way, an increased ratio of high-affinity to low-affinity sites in the raphe 
nuclei would provide an explanation for 8-OH-DPAT having greater efficacy in 
the raphe compared to the postsynaptic areas such as the hippocampus (Rabiner, 
Bhagwagar, Gunn, Cowen, & Grasby, 2004). 
MDMA-induced Deficits 
As outlined previously, MDMA abuse produces persistent cognitive 
impairments and mood disturbances, and increases the risk of developing 
psychological disorders. Evidence suggests that these long-term impairments are 
associated with neurochemical deficits induced by MDMA abuse. These deficits 
are primarily produced in the 5-HT system, as would be expected given the 
preferential effect MDMA has on the 5-HT system in comparison to other 
neurotransmitter systems. Time-course studies reveal two phases of MDMA-
induced 5-HT deficits in rats: a rapid acute phase and a long-term phase (Stone, 
Merchant, Hanson, & Gibb, 1987; Schmidt, 1987). During the first few hours 
following MDMA administration, brain tissue 5-HT is extensively depleted and 
TPH is largely inactive. Twenty-four hours later, tissue 5-HT levels recover to 
normal although TPH activity remains diminished. The long-term phase, 
beginning one week later and lasting for months, is characterised by tissue 5-HT 
depletion (Colado, Murray, & Green, 1993), sustained inactivation of TPH (Stone, 
Johnson, Hanson, & Gibb, 1989), reductions in 5-HIAA (Colado & Green, 1994), 
and reductions in serotonin transporter (SERT) binding (Battaglia, Yeh, & De 
Souza, 1988; Scanzello, Hatzidimitriou, Martello, Katz, & Ricaurte, 1993; O’Shea 
et al., 2006). Additionally, there is decreased immunoreactive 5-HT in fine axons 
and terminals in forebrain areas along with morphological abnormalities of 5-HT 
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axons and terminals (O’Hearn, Battaglia, De Souza, Kuhar, & Molliver, 1988; 
Fischer, Hatzidimitriou, Wlos, Katz, & Ricaurte, 1995). 
Numerous studies have explored the functional impact on the serotonin 
system of these MDMA-induced deficits. The overall finding is that MDMA 
exposure can cause reductions in the 5-HT response to stimuli that normally 
evoke a considerable response. Matuszewich, Filon, Finn and Yamamoto (2002) 
found that rats pretreated with MDMA showed a blunted 5-HT response to an 
immobilisation stress test in comparison to controls, as measured by microdialysis 
measures of synaptic overflow in 5-HT terminal regions. Similarly, Series, Cowen 
and Sharp (1994) and Shankaran and Gudelsky (1999) found that MDMA 
pretreatment markedly reduced the 5-HT response (by 45% in the frontal cortex 
and 55% in the striatum respectively) to the potent 5-HT releaser fenfluramine. 
Stimulating the 5-HT system with electrical stimulation of the DRN also produced 
markedly decreased 5-HT synaptic overflow in the frontal cortex, although not in 
the hippocampus, two weeks after MDMA treatment (Gartside, McQuade, & 
Sharp, 1996). Additionally, multiple studies with human and animal subjects have 
shown that MDMA pretreatment attenuated hormonal responses to 
neuroendocrine challenges that are likely to be mediated by the serotonergic 
system (Price, Ricaurte, Krystal, & Heninger, 1989; Poland, 1990; Poland et al., 
1997; Gerra et al., 1998; Gerra et al., 2000; Gouzoulis-Mayfrank, Becker, Pelz, 
Tuchtenhagen, & Daumann, 2002; Baumann, Clark, Franken, Rutter, & Rothman, 
2008). As decreased serotonergic neurotransmission has been found to impair a 
number of aspects of learning and memory (Altman, Nordy, & Ogren, 1984; 
McEntee & Crook, 1991), these findings suggest that MDMA-induced deficits 
lead to functional impacts on the 5-HT system that may underlie the cognitive and 
mood impairments seen with MDMA abuse. 
Compelling evidence linking MDMA-induced 5-HT deficits to cognitive 
impairments has been found in human subjects. Recreational users (greater than 
25 exposures) were seen to have significantly lower levers of cerebrospinal fluid 
(CSF) 5-HIAA than control subjects (McCann, Ridenour, Shaham, & Ricaurte, 
1994; McCann et al., 1999) and correlations between impairments and levels of 
CSF 5-HIAA have been found (Bolla, McCann, & Ricaurte, 1998), indicating a 
role of 5-HT deficits. Furthermore, neuroimaging studies have found lower 
 14 
densities of SERT binding sites in MDMA users that correlate with previous 
MDMA use and indicate structural changes to 5-HT neurons that may relate to 
cognitive and mood impairments (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 
1998; McCann et al., 2008). For instance, patients with unipolar major depression 
have been reported to have significantly reduced SERT binding density (Malison 
et al., 1998). 
These persistent MDMA-induced 5-HT deficits were originally thought to 
be the result of neurotoxicity - the loss of 5-HT terminals, projections and cells. In 
an ongoing debate, researchers have recently challenged this view on a number of 
fronts. Baumann (2007) for instance, argues that methods used to detect 5-HT 
nerve fibres, such as autoradiography, may be too insensitive to detect fibres that 
are still present, albeit markedly reduced in the TPH biomarker. Additionally, 
studies show that MDMA-induced reductions in 5-HT levels and SERT binding 
eventually recover (Battaglia et al., 1988; Scanzello et al., 1993), suggesting the 
possibility that 5-HT terminals are not destroyed (Buchert et al., 2006; Brennan & 
Schenk, 2006). 
To further this debate, a number of studies have compared the effects of 
MDMA with those of the archetypal 5-HT neurotoxin 5,7-DHT as a positive 
control. In these studies 5,7-DHT produces a profile of neuronal and glial 
responses that is consistent with neurotoxic damage, whereas MDMA does not 
(Xie et al., 2006; Wang, Baumann, Dersch, & Rothman, 2007; Baumann et al., 
2007). While both substances deplete brain tissue 5-HT, their actions differ in 
other key respects. The first is in measures of reactive gliosis - a marker of CNS 
damage characterised by hypertrophy of astrocytes and increase in glial fibrillary 
acidic protein (GFAP) (reviewed by O’Callaghan & Sriram, 2005). Established 
neurotoxins such as 5,7-DHT increase the levels of GFAP in rodent CNS, 
indicating this protein can be used as a sensitive marker of neuronal damage 
(O’Callaghan, Jensen, & Miller, 1995; O’Callaghan & Sriram, 2005). Pubill et al. 
(2003) found no increase in GFAP expression with a MDMA dosing regime (20 
mg/kg i.p. twice daily for 4 days) that depletes 5-HT. Bai, Jones, Lau and Monks 
(2001) also failed to find increased GFAP expression in rats after 10 mg/kg s.c. 
MDA. Thus MDMA does not exhibit the same reactive gliosis pattern of neuronal 
damage as the established neurotoxin 5,7-DHT. 
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The second respect in which MDMA differs from 5,7-DHT is in effects on 
the SERT protein. It is established that 5,7-DHT decreases SERT protein binding 
and expression (Wang, Baumann, Xu, & Rothman, 2004; Wang, Baumann, Xu, 
Morales, & Rothman, 2005). Conversely, administration of high-dose MDMA 
reduces SERT binding but does not alter the expression of SERT as indicated by 
SERT mRNA levels and immunohistochemistry (Wang et al., 2004; Wang et al., 
2005), even when, for example, binding is reduced by 82% (Wang et al., 2005). 
This raises the question of what effect MDMA has on the SERT protein. Earlier 
studies found no changes in the distribution of SERT protein between the plasma 
membrane and cytoplasmic areas following MDMA administration (Wang et al., 
2004; Wang et al., 2005). However Xie et al. (2006) and Kivell, Day, Bosch, 
Schenk and Miller (2010) have since questioned the specificity of the SERT 
antibody used in these studies, and recent research reveals that SERT proteins are 
down-regulated from the cell membrane to intracellular vesicles following 
MDMA administration (Kivell et al.). Furthermore, recent research with refined 
methods has also shown a profound reduction of SERT gene expression in rats 
due to MDMA (Biezonski & Meyer, 2010). Although this result appears to 
coalesce the effects of MDMA and 5,7-DHT, the decrease in SERT 
immunoreactivity found by Biezonski and Meyer was accompanied by only a 
minor decrease in vesicular monoamine transporter 2 (VMAT-2) protein levels, 
suggesting that MDMA-induced reductions in SERT are related to a down-
regulation phenomenon and are not necessarily dependent on neurotoxicity. 
Another factor in this debate is that some studies have shown MDMA-
induced 5-HT neurotoxicity through conventional markers of cell death 
(Commins et al., 1987; Jensen et al., 1993). These discrepancies may be explained 
by dosage differences, as such studies are likely to have used very high doses of 
MDMA (cumulatively ranging from 80 to 600 mg/kg) that cause nonspecific 
damage beyond 5-HT neurons and their projections (Baumann et al., 2007). 
Because of this, the evident neurotoxicity could be linked to other causal factors 
such as excessive sympathetic activation, hyperthermia and oxidative stress 
(Baumann et al., 2007; Puerta, Hervias, & Aguirre, 2009). 
In light of the findings of recovery and the largely non-neurotoxic profile of 
MDMA, the explanation of MDMA-induced 5-HT deficits that is most consistent 
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with available data is that they are due to persistent adaptive changes in protein 
function or gene expression. Evidence of such plastic neuroadaptive changes to 
repeated MDMA administration have been shown in the 5-HT system. The SERT 
and VMAT-2 expression results of Biezonski and Meyer (2010) confirm that the 
serotonergic neurons of the DRN and MRN undergo major neuroadaptations 
following high-dose MDMA treatment. Additionally, Aguirre, Frechilla, Garcia-
Osta, Lasheras and Del Rio (1997) found an increase in 5-HT1A receptor binding 
in the rat frontal cortex one week following repeated MDMA administration, 
correlated with enhanced 5-HT1A mRNA expression. Such neuroadaptations may 
underlie the cognitive and mood impairments seen following MDMA abuse. 
The nature of MDMA-induced neuroadaptations in the 5-HT system can be 
explored further by considering mechanisms that regulate 5-HT synthesis, as a 
notable aspect of MDMA-induced 5-HT deficits is a reduction in synthesis. 5-HT 
synthesis is primarily governed by protein levels and activity of the rate-limiting 
enzyme TPH (Fernstrom & Wurtman, 1971) and MDMA has been repeatedly 
shown to produce long-term reductions in TPH activity (Stone et al., 1987; 
Schmidt, 1987; Bonkale & Austin, 2008). Therefore, the long-term reductions in 
TPH activity are likely to be a critical factor in MDMA-induced 5-HT deficits. 
These reductions are not thought to be caused directly by MDMA, as MDMA has 
no effect on TPH in vitro (Capela et al., 2009). Rather, as MDMA-induced TPH 
inhibition is prevented by calcium channel blockers (Johnson et al., 1992), 
reductions in TPH protein and activity are strongly associated with 5-HT cell 
firing. 5-HT nerve impulse control is governed by 5-HT1A autoreceptors, the 
activation of which has been reliably shown to inhibit 5-HT cell firing in the 
raphe nuclei and to reduce 5-HT synthesis and release in the raphe nuclei and in 
5-HT terminal areas (Hjorth et al., 1982; Sprouse & Aghajanian, 1987; Hamon et 
al., 1988; Sprouse & Aghajanian, 1988; Hjorth & Magnusson, 1988; Blier & De 
Montigny, 1990; Bonvento, Scatton, Claustre, & Rouquier, 1992; Adell et al., 
1993; Kreiss & Lucki, 1994). In particular, studies have shown that 5-HT1A 
agonists applied directly to the DRN and MRN results in a decrease in 5-HT 
synthesis in terminal areas as measured by estimates of the in vivo rate of TPH 
activity (Hjorth & Magnusson, 1988; Hillegaart, Hjorth, & Ahlenius, 1990). 
Therefore, the 5-HT1A autoreceptor can regulate 5-HT synthesis, and hence might 
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mediate a key deficit produced by MDMA. It follows that functional changes in 
the 5-HT1A receptor would have a pronounced impact on the 5-HT system, and the 
cognitive, learning and mood processes reliant on 5-HT functioning. 
Neuroadaptations in the 5-HT1A receptor 
A number of studies have found neuroadaptive changes in the sensitivity of 
the 5-HT1A autoreceptor produced by psychostimulants including MDMA. In rats 
treated with cocaine (15 mg/kg i.p. for 7 days) the inhibitory response of DRN 5-
HT neurons to an 8-OH-DPAT challenge was increased, indicating enhanced 
sensitivity of the 5-HT1A autoreceptors (Cunningham, Paris, & Goeders, 1992). 
Repeated treatment with amphetamine (5 mg/kg i.p. twice daily for 6 days) also 
enhanced 5-HT1A sensitivity, as indicated by increased [3H]-8-OH-DPAT binding 
in the DRN (Bonhomme, Cador, Stinus, Le Moal, & Spampinato, 1995). With 
MDMA, Renoir et al. (2008) demonstrated that MDMA pretreated mice (20 
mg/kg, twice daily for four days) had a significantly greater sensitivity to the 5-
HT1A agonist ipsapirone, as measured by greater inhibition of DRN 5-HT neuron 
firing. The authors also found that the spontaneous in vitro firing of mice DRN 5-
HT neurons was significantly reduced four weeks after MDMA treatment. These 
findings are indicative of long-term MDMA-induced changes that increase the 
sensitivity of the 5-HT1A autoreceptor. This increase in sensitivity can be termed 
'supersensitisation'. 
Further evidence of sensitivity increases in the 5-HT1A autoreceptor comes 
from investigations into the hypothermic response to 5-HT1A agonists. This 
hypothermic effect is thought to be 5-HT1A-mediated, although there is debate in 
the literature over the contribution of heteroreceptors and autoreceptors. It has 
been shown that direct application of 8-OH-DPAT into the DRN produced the 
hypothermic response in rats and the effect was inhibited by selective 5-HT1A 
antagonists (Higgins, Bradbury, Jones, & Oakley, 1988; Hillegaart, 1991). 
Additionally, Rusyniak et al. (2007) found that microinjections of WAY 100635 
into the rostral raphe pallidus (rRP) significantly attenuated 8-OH-DPAT (0.2 
mg/kg i.p.)-elicited hypothermia, suggesting the role of 5-HT1A autoreceptors on 
5-HT neurons in the rRP (Helke, Capuano, Tran, & Zhuo, 1997). However, the 
buspirone analogue BMY 7378, which is a high-efficiency agonist at 5-HT1A 
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receptors in the DRN but a low-efficiency agonist in terminal areas, failed to 
produce a hypothermic effect when directly infused in to the DRN (O’Connell, 
Sarna, & Curzon, 1992). Although the mechanisms behind thermoregulation are 
complex, the available evidence suggests that 8-OH-DPAT produces its 
hypothermic response at least in large part via 5-HT1A autoreceptors. 8-OH-DPAT 
was found to enhance the hypothermic response in mice that had been treated with 
MDMA four weeks previously (Bill, Knight, Forster, & Fletcher, 1991). Aguirre 
et al. (1998) also found a potentiated hypothermic response to 8-OH-DPAT in rats 
one week after a single administration (30 mg/kg i.p.) of MDMA. Therefore, there 
is evidence that MDMA pretreatment produces sensitivity changes in the 5-HT1A 
receptors, resulting in an enhanced hypothermic response, through a putative 5-
HT1A autoreceptor mediated mechanism. 
Another means of investigating the functional status of the 5-HT1A 
autoreceptor is through its effects on 5-HT synthesis. Changes in sensitivity of the 
5-HT1A autoreceptor can be assessed by in vivo measurements of serotonin 
synthesis, as this is mediated by 5-HT1A autoreceptor activation. Serotonin 
synthesis can be measured in vivo by inhibiting the reaction from 5-HTP to 5-HT, 
causing the accumulation of 5-HTP in the cytoplasm that acts as a measure of the 
rate of 5-HT synthesis (Carlsson, Davis, Kehr, Lindqvist, & Atack, 1972). Studies 
with ethanol, a substance also liable to abuse and to cause long-term impairments 
in learning and cognition, implicate supersensitised 5-HT1A receptors as involved 
in impairments through measures of 5-HT synthesis. Kelaï et al. (2008) and 
Esteban, Moranta, Sastre-Coll, Miralles and Garcia-Sevilla (2002) found that 
inhibition of 5-HTP accumulation was significantly more pronounced in ethanol 
pretreated mice. Both of these results indicate supersensitisation of the 
autoreceptor following ethanol pretreatment, resulting in greater inhibition of 5-
HT synthesis. 
The Current Study 
As previously described, MDMA abuse causes persistent deficits in the 5-
HT system leading to impairments in cognition and mood. The 5-HT1A receptor 
has been shown to be implicated in these deficits, possibly by way of 
neuroadaptations that impact on 5-HT neuron functioning. The aim of this thesis 
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is to investigate changes in 5-HT1A autoreceptor sensitivity following repeated, 
high-dose MDMA administration. An autoreceptor selective dose of 8-OH-DPAT 
can be used to test for neuroadaptive changes in 5-HT1A autoreceptor sensitivity 
following MDMA pretreatment. The sensitivity changes can be measured in two 
ways: the effect on 5-HT synthesis, and the hypothermic response. With respect to 
these two measures of receptor functioning, it is hypothesised that MDMA 
pretreatment will increase the sensitivity of the 5-HT1A autoreceptor, as realised in 
two ways. First, it is hypothesised that MDMA pretreated rats will accumulate 
significantly less 5-HTP following 8-OH-DPAT administration in comparison to 
saline controls. Second, it is hypothesised that MDMA pretreated rats will have a 
potentiated hypothermic response to 8-OH-DPAT administration in comparison to 
saline controls. Furthermore, it is theorised that the MDMA-induced 
supersensitisation of the 5-HT1A autoreceptor is critical in the expression of long-
term serotonergic deficits, through a sensitised down-regulation of 5-HT synthesis 
and release. This sensitised down-regulation is thought to lead to the cognitive 
and mood impairments seen with MDMA abuse. 
This study is unique because it is the first to investigate MDMA-induced 
changes in the sensitivity of the 5-HT1A autoreceptor using 5-HTP accumulation 
in vivo with an autoreceptor selective 5-HT1A agonist. Previous investigations of 
5-HT1A autoreceptor sensitivity have used the hypothermic effect (Renoir et al., 
2008), but not a 5-HTP accumulation measure of 5-HT synthesis. Additionally, 
previous studies (for example O’Shea et al., 2006) that have measured 5-HTP 
accumulation following MDMA pretreatment have not done so in the context of a 
5-HT1A receptor agonist and therefore are unable to associate changes in 5-HT1A 
sensitivity to MDMA-induced deficits. 
It is hoped that the results of the experiments will further clarify the 
mechanisms behind cognitive and mood impairments resulting from MDMA 
abuse. Greater fundamental knowledge of these mechanisms will inform future 
research towards the development of novel pharmaceutical therapies to improve 
the wellbeing of those suffering the effects of MDMA, and other 
psychostimulants abuse.  
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Method 
Subjects 
The subjects were male Sprague-Dawley rats weighing 172-226g. The rats 
were from a population bred in the vivarium at Victoria University of Wellington. 
Rats were housed in a 12 hour light-dark cycle, with temperature (21°C) and 
humidity (77%) controlled. Tests were conducted during the light portion of the 
cycle, between 08:00 and 17:00 hours. Food and water were available ad libitum 
except during the six MDMA administration hours in Experiments 2 and 2b. 
The Victoria University of Wellington Institutional Animal Ethics 
Committee has approved all protocols used in the experiments. 
Experimental Procedures 
Using 5-HTP as a marker of 5-HT1A sensitivity 
Changes in sensitivity of the 5-HT1A autoreceptor were assessed by in vivo 
measurement of serotonin synthesis using the 5-HTP accumulation method with 
3-hydroxybenzylhydrazine dihydrochloride (NSD-1015) (Carlsson et al., 1972). 
NSD-1015 is a potent inhibitor of the aromatic amino acid decarboxylase enzyme 
that catalyses the decarboxylation reaction of 5-HTP to 5-HT. By inhibiting the 
decarboxylase enzyme, NSD-1015 causes the accumulation of 5-HTP in the 
cytoplasm. As 5-HTP is formed by the hydroxylation of L-tryptophan by TPH, 
NSD-1015 acts as a measure of TPH activity. 
Measurement of 5-HTP accumulation can be regarded as a measure of 5-HT 
synthesis because the conversion involves a single compartment system (Tozer, 
Neff, & Brodie, 1966). As activation of the 5-HT1A autoreceptor inhibits 5-HT 
synthesis, and therefore reduces the rate of TPH, the 5-HTP accumulated in the 
presence of a 5-HT1A agonist acts as a measure of the sensitivity of the 
autoreceptor. An increase in the sensitivity of the autoreceptor, as hypothesised in 
the current experiments, would result in a down-regulation of 5-HT synthesis and 
hence TPH activity, leading to less 5-HTP being available for accumulation and 
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measurement. The selective 5-HT1A agonist 8-OH-DPAT is used in the current 
experiments to activate the autoreceptor prior to NSD-1015 administration. The 
decarboxylase inhibition method is necessary as otherwise there would not be a 
sufficient concentration of 5-HTP to allow measurement given that the conversion 
of 5-HTP to 5-HT is immediate and almost total (Carlsson, Bédard, Lindqvist, & 
Magnusson, 1972). 
Determination of 5-HTP, 5-HT and 5-HIAA 
Thirty minutes following NSD-1015 administration rats were rendered 
unconscious by CO2, decapitated and their brains rapidly extracted. The brains 
were sliced using an ice-cold stainless steel brain block following the procedures 
of Heffner, Hartman and Seiden (1980). The frontal cortex, striatum and 
hippocampus were dissected, placed in labelled vials, weighed, and then stored at 
-80°C until analysed. 
Analysis to determine tissue concentrations of neurochemicals was 
performed by High Performance Liquid Chromatography with Electrochemical 
Detection (HPLC-ED), following procedures outlined by Hamon et al. (1988) and 
Kelaï et al. (2008). Tissue samples were removed from the freezer, homogenised 
in 10 volumes of 0.1N perchloric acid and centrifuged at 12,000g for 30 min at 
4°C. The supernatant was filtered and injected into the HPLC-ED system (Agilent 
1100 series). The injection volume was 5 µL for the striatum and 20 µl for the 
other regions. Constituent chemicals were separated using a C18 reversed phase 
column (150 × 4.6 mm, 5 µm particle size; Eclipse XDB-C18, Agilent, USA). The 
mobile phase consisted of NaH2PO4 (75 mM), octane-1-sulphonic acid (1.7 mM), 
EDTA (0.25 mM), triethylamine (100 µL/L) and acetonitrile (10%), and was 
adjusted to pH 3 with phosphoric acid. The flow rate was 1 ml/min. Detection was 
performed using a coulometric detector (Coulochem III, ESA, USA). The guard 
cell potential was set at 450 mV and the analytical cell potentials at -175 and 325 
mV. Working external standards (500 - 15.125 ng/ml in 0.1 N perchloric acid) 
were prepared daily from standard stock solutions. Chromatograms were acquired 
with ChemStation software (Agilent, USA). Peak heights of standards and 
samples were measured, and the concentrations in samples were calculated from 
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the regression curves obtained from standards. Concentrations are expressed as ng 
per mg of tissue. 
Using hypothermia as a marker of 5-HT1A sensitivity 
The hypothermic response to 8-OH-DPAT (Goodwin, De Souza, Green, & 
Heal, 1987), mediated by a putative 5-HT1A autoreceptor mechanism, was used to 
provide an indicator of 5-HT1A autoreceptor sensitivity. A lubricated digital rectal 
thermometer probe (Surgipack Digital Thermometer, Code 6344) was inserted 2 
cm into the rectum immediately prior to administration of 8-OH-DPAT to 
establish a baseline, and 30 minutes post administration. Rats were lightly 
restrained by hand until the temperature stabilised (no longer than 30 seconds at 
any time), using a method adapted from Ho et al. (2004). All readings were taken 
in the temperature controlled (21°C) home room. Previous studies have found the 
peak hypothermic effect at this 30 minute time point post administration (Hjorth, 
1985).  
Experiment 1 - Method validation 
A range of low, autoreceptor-selective doses of the 5-HT1A agonist 8-OH-
DPAT doses were administered, together with NSD-1015, to confirm 8-OH-
DPAT’s effect on 5-HT synthesis and the general effects of NSD-1015. No 
MDMA pretreatment was performed in this experiment. 
A total of 35 drug naïve rats received one of the following doses of 8-OH-
DPAT: 0.025, 0.05, 0.1 mg/kg s.c. or saline (0.9% NaCl, 1 ml/kg, s.c.). Thirty 
minutes after 8-OH-DPAT administration, NSD-1015 (100 mg/kg i.p.) was 
administered, a dose that has been shown to produce complete inhibition of the 
rate-limiting decarboxylase enzyme (Carlsson et al., 1972). Of those that received 
saline, there was also a smaller control group (n = 5) that did not receive NSD-
1015, receiving saline (100 ml/kg i.p.) instead. 
Rats were then processed to determine 5-HTP, 5-HT and 5-HIAA levels as 
described in the experimental procedures. 
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Experiment 2 - Effect of MDMA pretreatment on 5-HT1A sensitivity 
In order to test for increased sensitivity of the 5-HT1A autoreceptor 
following repeated MDMA exposure, a MDMA administration regime of four 10 
mg/kg i.p. injections spaced two hours apart was chosen, giving a total dose of 40 
mg/kg i.p. over a 6 hour period. Of a total of 80 rats, 40 received MDMA and 40 
received saline. The schedule and dose were chosen because they have been 
shown to reliably produce significant 5-HT deficits in 5-HT markers (Scanzello et 
al., 1993; Fischer et al., 1995; Sumnall et al., 2004; Nair & Gudelsky, 2006; 
Brennan & Schenk, 2006), a suppression of MDMA-induced 5-HT response 
(Shankaran & Gudelsky, 1999) and a downward shift in the dose–effect curve for 
MDMA-induced hyperactivity (Brennan & Schenk, 2006). Additionally, the 
repeated dosing regimen attempts to approximate the effects of the common 
practice of sequential dosing (‘bumping’) often used by human subjects (Parrott, 
2001; Sanchez et al., 2004). During this regime the rats were individually housed. 
Following MDMA administration, rats were collectively housed in cages of 
five animals for a period of two weeks. This time period was chosen because 
deficits in tissue 5-HT and 5-HIAA concentrations, and alterations to 5-HT 
receptors, have been demonstrated following two weeks (Shankaran & Gudelsky, 
1999; Reneman et al., 2002). 
After two weeks, measurement of the sensitivity of the 5-HT1A autoreceptor 
was performed using the 5-HTP accumulation and the hypothermic response 
methods as described previously. 8-OH-DPAT (0, 0.025, 0.05, or 0.1 mg/kg s.c.) 
and NSD-1015 (100 mg/kg i.p.) were administered as in Experiment 1. Rats were 
then processed to determine 5-HTP, 5-HT and 5-HIAA levels as described in the 
experimental procedures. 
Experiment 2b - Additional 8-OH-DPAT doses 
In response to the results of Experiment 2, further lower doses of 8-OH-
DPAT were tested (see Results for more details). The procedures of Experiment 2 
were repeated with a total of 60 rats, half receiving MDMA pretreatment, and 8-
OH-DPAT being administered at different doses: 0.00625, 0.0125 mg/kg s.c. 8-
OH-DPAT, or saline (0.9% NaCl, 1ml/kg, s.c.). 
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Of the rats administered saline instead of 8-OH-DPAT, there were also two 
groups (one MDMA pretreated and one not) that did not receive NSD-1015 and 
acted as saline controls instead.  
Statistical Analyses 
Differences in tissue neurochemical levels and temperature changes 
between groups were assessed using one-way and two-way analysis of variance 
(ANOVA), and appropriate post-hoc tests where applicable. GraphPad Prism 5 
and SPSS Statistics 18 were used. 
Drugs 
±MDMA HCl (ESR Ltd, Porirua, New Zealand) was dissolved in saline at 
the concentration of 10 mg/ml and injected at a volume of 1 ml/kg i.p. MDMA 
purity was examined by gas chromatography and nuclear magnetic resonance 
spectroscopy, and assessed at greater than 98%. 
±8-OH-DPAT HBr (Tocris, Bristol, UK) was dissolved in saline at the 
concentration of 0.1 mg/ml, then further diluted to achieve appropriate 
concentrations; injections were at a volume of 1 ml/kg, s.c. 
NSD-1015 (Sigma, Auckland, New Zealand) was dissolved in degassed 
saline at the concentration of 20 mg/ml and injected at a volume of 5 ml/kg, i.p. 
Drug doses refer to the salt. 
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Results 
Experiment 1 
In Figure 1, the effect of NSD-1015 in inhibiting the decarboxylase enzyme 
is shown through the accumulation of 5-HTP (a), and the effect on 5-HT levels (b) 
and 5-HIAA levels (c) in the frontal cortex. An unpaired t test revealed that 
between saline control rats that received NSD-1015 (M = .11, SD = .02) and those 
that did not (M = .0096, SD = .0006), NSD-1015 induced a statistically significant 
1061% increase in 5-HTP tissue levels, p < .0001. This result shows the efficacy 
of NSD-1015 in inhibiting the decarboxylase enzyme leading to 5-HTP 
accumulation, and hence supports the validity of this aspect of the experimental 
method.  
It is interesting to note that tissue 5-HT levels were also significantly 
increased (27%) by NSD-1015 treatment between ‘Saline’ rats (M = .37, SD 
= .036) and those that received NSD-1015 (M = .47, SD = .05), p < .01. 
Furthermore, NSD-1015 caused a significant 37% decrease in tissue 5-HIAA 
levels between ‘Saline’ rats (M = .25, SD = .024) and those that received NSD-
1015 (M = .16, SD = .039), p < .001. 
 
 
Fig. 1.   The effects of NSD-1015 (100 mg/kg i.p.) in the frontal cortex on 5-HTP 
accumulation (a), 5-HT tissue levels (b) and 5-HIAA tissue levels (c) 30 minutes 
following NSD-1015 administration. Mean values are plotted and error bars 
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represent the SEM. Asterisks represent statistical significance from controls that 
did not receive NSD-1015, with ** p < .01 and *** p < .001. 
 
Comparisons of the 5-HT turnover rate between ‘Saline’ rats (M = .66, SD 
= .075) and those that received NSD-1015 (M = .34, SD = .11) revealed that the 
decarboxylase inhibitor induced a 49% decrease in 5-HT turnover, p < .0001. 
Figure 2 shows the effect of 8-OH-DPAT (0, 0.025, 0.05 and 0.1 mg/kg s.c.) 
on 5-HTP tissue levels in the frontal cortex (a) and hippocampus (b). For the 
frontal cortex, a one-way ANOVA revealed a significant main effect of 8-OH-
DPAT treatment on 5-HTP concentration, F (3, 34) = 22.26, p < .0001. Tukey’s 
post-hoc comparisons of the four doses indicate that the 0.05 mg/kg dose (M = 
0.085, SD = .016) and the 0.1 mg/kg dose (M = .054, SD = .0065) induced 
significantly lower 5-HTP accumulation in comparison to saline controls, p < .01 
and p < .001 respectively. 
In the hippocampus, a one-way ANOVA revealed a significant effect of 8-
OH-DPAT treatment on 5-HTP concentration, F (3, 34) = 21, p < .0001. Tukey’s 
post-hoc comparisons of the four doses indicate that the 0.1 mg/kg dose (M = .1, 
SD = .014) induced significantly less 5-HTP accumulation in comparison to saline 
controls, p < .001. Data for the striatum is not available.  
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Fig. 2.   5-HTP accumulation (ng/mg) one hour following 8-OH-DPAT treatment (0, 
0.025, 0.05 or 0.1 mg/kg s.c.) and 30 minutes following NSD-1015 (100 mg/kg i.p.) 
treatment in the frontal cortex (a) and hippocampus (b). Mean values are plotted 
and error bars represent the SEM. Asterisks represent statistical significance from 
saline controls, with ** p < .01 and *** p < .001. 
 
Experiment 2 
In this experiment, the 8-OH-DPAT doses from Experiment 1 were used to 
probe the 5-HT1A autoreceptor two weeks following MDMA pretreatment.  
Figure 3 shows the effect of 8-OH-DPAT on 5-HTP tissue levels in the 
frontal cortex (a), striatum (b) and hippocampus (c) between MDMA pretreated 
rats and saline controls. In the frontal cortex, a two-way ANOVA (pretreatment X 
8-OH-DPAT dose) revealed a sole main effect for 8-OH-DPAT dose, F (3, 72) = 
14, p < .0001. The interaction between pretreatment and 8-OH-DPAT dose was 
not significant, F (3, 72) = 1.3, p > .05. There does however appear to be a 
nonsignificant trend of lower 5-HTP levels in MDMA rats at the .025 mg/kg dose 
of 8-OH-DPAT. In the striatum there was a sole main effect of 8-OH-DPAT dose, 
F (3, 72) = 19.37, p < .0001. The interaction between pretreatment and 8-OH-
DPAT dose was not significant, F (3, 72) = .78, p > .05. In the hippocampus, there 
was a sole main effect of 8-OH-DPAT dose, F (3, 72) = 13.39, p < .0001. The 
interaction between pretreatment and 8-OH-DPAT dose was not significant, F (3, 
72) = 1.5, p > .05. 
These results indicate that MDMA pretreatment did not lead to 8-OH-DPAT 
having a more pronounced effect in reducing 5-HTP accumulation levels 
following decarboxylase inhibition. 
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Fig. 3.   5-HTP accumulation in the frontal cortex (a), striatum (b) and 
hippocampus (c) in rats two weeks following pretreatment with MDMA (4x 10 
mg/kg i.p.) or saline. To measure 5-HTP accumulation, 8-OH-DPAT (0, 0.025, 0.05, 
or 0.1 mg/kg s.c.) was administered, followed 30 minutes later by NSD-1015 (100 
mg/kg i.p.), and then brains were extracted 30 minutes after NSD-1015. Mean 
values are plotted and error bars represent the SEM. For all groups, n = 10. 
 
To determine the effect of MDMA pretreatment in inducing 5-HT deficits, 
analyses of 5-HT and 5-HIAA tissue levels were performed. Figure 4 shows this 
analysis for the frontal cortex (a, d), striatum (b, e) and hippocampus (c, f) 
between MDMA pretreated rats and saline controls. The only significant 
difference between the groups was found in the hippocampal 5-HT levels. For this 
region an unpaired t test revealed that rats that received MDMA pretreatment (M 
= .57, SEM = .025) had significantly reduced 5-HT tissue levels than saline 
controls (M = .74, SEM = .041), p < .01. 
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Fig. 4.   5-HT and 5-HIAA tissue levels in the frontal cortex (a, d), striatum (b, e) 
and the hippocampus (c, f) in rats two weeks following MDMA (4x 10 mg/kg i.p.) 
or saline pretreatment, and without 8-OH-DPAT but with NSD-1015 (100 mg/kg 
i.p.) administration 30 minutes prior to brain extraction. Mean values are plotted 
and error bars represent the SEM. For all groups, n = 10. Asterisks represent 
statistical significance from saline controls, with ** p < .01. 
 
Figure 5 shows the change in core body temperature values for MDMA and 
saline pretreated rats as a result of 8-OH-DPAT treatment. A two-way ANOVA 
(pretreatment X 8-OH-DPAT dose) revealed a sole main effect for 8-OH-DPAT 
dose, F (3, 72) = 57, p < .0001. The interaction between pretreatment and 8-OH-
DPAT dose was not significant, F (3, 72) = 1.6, p > .05. 
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Fig. 5.   Change in rectal core body temperature as a result of 8-OH-DPAT 
treatment for both MDMA (4x 10 mg/kg i.p.) and saline pretreated rats. 
Temperature measurements were assessed by rectal probe immediately prior to 8-
OH-DPAT injection s.c. and 30 minutes post injection. Mean values are plotted 
and error bars represent the SEM. For all groups, n = 10. 
 
The results of Experiment 2 suggested that there could be an effect of 
MDMA pretreatment at lower doses of 8-OH-DPAT. The nonsignificant 
difference between MDMA and saline groups at the 0.025 mg/kg 8-OH-DPAT 
dose, seen most clearly in the frontal cortex (Figure 3a), suggested that lower 
doses further may elucidate an effect due to MDMA pretreatment. Furthermore, 
the large difference between the saline pretreatment groups between 8-OH-DPAT 
doses 0/saline and 0.025 mg/kg suggested that there was scope for lower doses to 
complete the dose-response relationship. Experiment 2b was performed as an 
extension to Experiment 2 to test lower doses of 8-OH-DPAT. 
Experiment 2b 
In Experiment 2b, two lower doses of 8-OH-DPAT were tested, 0.00625 
mg/kg and 0.0125 mg/kg. Figure 6 shows the effect of these doses on 5-HTP 
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accumulation in the frontal cortex (a), striatum (b) and hippocampus (c) of 
MDMA and saline pretreated rats. 
In the frontal cortex, a two-way ANOVA (pretreatment X 8-OH-DPAT 
dose) revealed a sole main effect for pretreatment, F (1, 44) = 4.1, p < .05, 
indicating that MDMA pretreated rats have significantly lower 5-HTP levels 
across all 8-OH-DPAT doses. The interaction between pretreatment and 8-OH-
DPAT dose was not significant, F (2, 44) = .55, p > .05. Bonferroni post-hoc tests 
found no significant differences between the group means.  
In the striatum there was a sole main effect of 8-OH-DPAT dose, F (2, 44) 
= 1.7, p < .01. The interaction between pretreatment and 8-OH-DPAT dose was 
not significant, F (2, 44) = 1.7, p > .05. In the hippocampus, there was no 
significant main effects and the interaction between pretreatment and 8-OH-
DPAT dose was not significant, F (3, 72) = 1.5, p > .05. 
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Fig. 6.   5-HTP accumulation in the frontal cortex (a), striatum (b) and 
hippocampus (c) in rats two weeks following pretreatment with MDMA (4x 10 
mg/kg i.p.) or saline. To measure 5-HTP accumulation, 8-OH-DPAT (0, 0.0625, or 
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0.0125 mg/kg s.c.) was administered, followed 30 minutes later by NSD-1015 (100 
mg/kg i.p.), and then brains were extracted 30 minutes after NSD-1015. Mean 
values are plotted and error bars represent the SEM. 
 
Experiment 2b included a group that did not receive NSD-1015 to 
determine if the 5-HT deficit is being induced by MDMA in the rats. Figure 7 
shows the results of this analysis for control rats that did not receive 8-OH-DPAT. 
No significant differences in 5-HT or 5-HIAA tissue levels were found between 
Saline and MDMA pretreated rats using t tests. 
 
 
Fig. 7.   5-HT tissue levels for the frontal cortex (a), striatum (b) and hippocampus 
(c) of rats that received either Saline or MDMA (4x 10mg/kg i.p.) pretreatment, 
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without 8-OH-DPAT or NSD-1015 administration. 5-HIAA levels for the frontal 
cortex (d), striatum (e), hippocampus (f) for the same groups. Mean values are 
plotted and error bars represent the SEM. For all groups, n = 5. 
 
Figure 8 shows the change in core body temperature values for MDMA and 
saline pretreated rats as a result of 8-OH-DPAT treatment. A two-way ANOVA 
revealed no significant effects. 
 
 
Fig. 8.   Change in rectal core body temperature as a result of 8-OH-DPAT 
treatment for both MDMA (4x 10 mg/kg i.p.) and saline pretreated rats. 
Temperature measurements were assessed by rectal probe immediately prior to 8-
OH-DPAT injection s.c. and 30 minutes post injection. Mean values are plotted 
and error bars represent the SEM. 
 
The 5-HT tissue level results presented in Experiment 2 and 3 above do not 
show a clear effect of MDMA pretreatment in terms of 5-HT deficits. To 
investigate a possible source of variability in the results, and to determine if there 
is a relationship between rat weight and MDMA-induced deficits, correlations 
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between rat weight at the time of pretreatment and later neurochemical results 
were performed.  
Figure 9 shows relationships between rat weight at pretreatment day and 5-
HT tissue concentrations two weeks later on processing day for control rats that 
received MDMA pretreatment and no 8-OH-DPAT or NSD-1015. It is important 
to remove the confounding factors of 8-OH-DPAT and NSD-1015 due to their 
effects on the 5-HT system. The frontal cortex (a), striatum (b) and hippocampus 
(c) are shown. 
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Fig. 9.   Relationship between 5-HT tissue levels and pretreatment weight, in the 
frontal cortex (a), striatum (b) and hippocampus (c) for rats in the MDMA 
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pretreatment (4x 10 mg/kg i.p.), no 8-OH-DPAT, no NSD-1015 control group. n = 
5. 
 
Pearson’s r analysis reveals moderately strong negative correlations in all 
three regions, r = -.58, -.65 and -.65 for the frontal cortex, striatum and 
hippocampus respectively. However, with only five values the results are not 
statistically significant, p > .5 in all cases. Hence there is a trend that lighter rats 
have higher 5-HT tissue levels than heavier rats. 
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Discussion 
The current experiments were performed to test the hypothesis that high-
dose, repeated MDMA treatment causes an increase in sensitivity of the 5-HT1A 
autoreceptor. Unexpectedly, the results of the primary experiment indicated that 
MDMA pretreatment did not cause increased sensitivity of the 5-HT1A 
autoreceptor, as determined by the two measures of sensitivity. No significant 
differences in 5-HTP tissue levels between saline and MDMA pretreated rats, at 
all doses of 8-OH-DPAT, were found two weeks following pretreatment. 
Additionally, the hypothermic response to 8-OH-DPAT was not sensitised in 
MDMA pretreated rats in comparison to controls, thereby also not providing 
evidence of increased 5-HT1A sensitivity. 
The additional investigation of lower 8-OH-DPAT doses also did not find 
evidence of an increase in 5-HT1A sensitivity. The lower doses of 8-OH-DPAT 
did not induce less 5-HTP accumulation in the MDMA pretreated rats, and no 
significant difference in hypothermic response was found between MDMA and 
saline groups. Therefore, the results of both experiments in the current study do 
not support the hypothesis that high-dose, repeated MDMA treatment increases 
the sensitivity of the 5-HT1A autoreceptor. 
To investigate why no significant changes in 5-HTP accumulation or 
hypothermic effect were found, the first area of interest is the validity of the 
procedure in measuring the variables under examination. NSD-1015 acted as 
expected in inhibiting the conversion of 5-HTP to 5-HT and dramatically 
increasing 5-HTP levels. Additionally, 8-OH-DPAT was found to produce the 
expected result in decreasing accumulated 5-HTP levels, presumably via 
activation of 5-HT1A autoreceptors (Hjorth et al., 1982; Hjorth, 1985; Hillegaart, 
1991). Hence the methodology appears sound in these regards, although possible 
reasons for not finding MDMA-induced changes in 5-HTP accumulation or 5-
HT1A hypothermia can be investigated further. 
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5-HT Deficits 
One important factor that could explain why there are no sensitivity changes 
due to MDMA is that there is weak evidence in the current experiments of the 
expected MDMA-induced 5-HT deficits in control rats that did not receive 8-OH-
DPAT. Only in the hippocampus (Figure 4c) was there a significant difference in 
5-HT levels between saline and MDMA groups, with the MDMA pretreatment 
group at 77% of control. A substantial reduction in 5-HT and 5-HIAA tissue 
levels would be expected given the results of other studies that have found such 5-
HT deficits in the frontal cortex, striatum and hippocampus two weeks following 
MDMA doses of 4x 10 mg/kg i.p. For example, with this dosing regime Scanzello 
et al. (1993) reported 5-HT levels in MDMA pretreated rats as 22% of control in 
the frontal cortex, 58% of control in the striatum and 34% of control in the 
hippocampus. Additionally, with the same MDMA regime Fischer et al. (1995) 
reported similar reductions in 5-HIAA tissue levels, to 35% of control in the 
frontal cortex, 40% of control in the striatum and 32% of control in the 
hippocampus. The lack of 5-HT deficits in the current study is a critical issue, as it 
does not allow the original hypothesis that MDMA supersensitises the 5-HT1A 
autoreceptor to be properly addressed. While it may be possible that MDMA-
induced changes in 5-HT1A autoreceptor sensitivity could occur without 
conventional 5-HT deficits, without evidence of these 5-HT deficits there is less 
basis on which to expect changes in the autoreceptor. 
A potential reason for the unsubstantial evidence of MDMA-induced 5-HT 
deficits was the effect of NSD-1015 on the serotonin system, presented in Figure 
1. The drug acted to significantly increase 5-HT levels by 27%, decrease 5-HIAA 
levels by 37%, and decrease 5-HT turnover by 49%. A possible explanation of 
these results is that compensatory mechanisms act to maintain 5-HT levels by 
reducing catabolism of the neurotransmitter as a result of having a severely 
inhibited tryptophan enzyme. Therefore, the effects of NSD-1015 could have 
overshadowed the expected 5-HT deficits produced by MDMA. To test this, a 
group that did not receive NSD-1015 was analysed to determine if the MDMA-
induced 5-HT deficits were present (Figure 7). No significant difference in 5-HT 
or 5-HIAA levels between saline and MDMA pretreated rats was also found in 
 41 
these groups that did not receive NSD-1015. Therefore, the NSD-1015 treatment 
is not impacting on the 5-HT deficits that should be produced by MDMA. The 
lack of substantial 5-HT deficits casts doubt on the efficacy of the MDMA 
pretreatment regime to produce deficits in the particular sample of rats used in the 
current experiments. To investigate this further it is worth examining the 
characteristics of these rats. 
Rat Characteristics 
There are a number of possible reasons why there was no strong evidence of 
MDMA-induced 5-HT deficits in the rats used. It is known that the extent of 
MDMA-induced serotonergic deficits in rats is determined by dose, dosing regime, 
rat strain, body temperature and age (Broening, Bowyer, & Slikker, 1995; O’Shea, 
Granados, Esteban, Colado, & Green, 1998; Green, Mechan, Elliott, O’Shea, & 
Colado, 2003). Previous research, as described earlier, has shown significant 5-
HT deficits in rats with the same dose, dosing regime and strain as used in the 
current experiments. However, much of this research uses larger adult rats that are 
more susceptible to MDMA-induced 5-HT deficits. For example, Scanzello et al. 
(1993) reported significant 5-HT deficits with Sprague-Dawley rats at PD 77, 
weighing approximately 350g. The weight, and hence age, of the rats used in the 
current experiments is a potential reason for the lack of 5-HT deficits. 
The rats used in the current experiments had a mean weight of 198g, with a 
range between 172g and 226g. The ages of the rats in post natal days (PD) are 
unknown, although they can be estimated from a Sprague-Dawley weight chart 
(Harlan Labs, 2009), giving a range of approximately PD 42 to PD 50, with a 
mean of PD 46. This age range puts the rats in their adolescence, a 
neurodevelopmental stage characterised in all species by extensive change, with 
the serotonergic system undergoing substantial reorganisation (Spear, 2000). For 
instance, Chen, Turiak, Galler and Volicer (1997) reported that hippocampal 5-
HT levels in rats at PD 45 were six times higher than at juvenile and adult ages. 
Furthermore, Broening, Bacon and Slikker (1994) showed that MDMA has 
varying effects on individual neurochemical components at different 
developmental stages. Due to these factors, MDMA has more variable effects in 
adolescent rats and 5-HT deficits, if they develop at all, are more transient. 
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It has been reported that rats up to PD 35–40 do not exhibit MDMA-
induced 5-HT deficits following 10–40 mg/kg MDMA, as evidenced by there 
being no significant decrease in 5-HT transporter density or 5-HT levels 
(Broening et al., 1994). The researchers showed that PD 40 is the approximate age 
at which susceptibility to 5-HT deficits begins. Fone et al. (2002) demonstrated 
that even this might be conservative, as they reported no 5-HT deficits in PD 40 
rats 12 days following a MDMA dosing regime of 45 mg/kg over a period of 3 
days. Therefore the majority of the rats used in this study were close to the age at 
which MDMA-induced 5-HT deficits begin to manifest, and therefore had a 
considerably low likelihood of developing lasting 5-HT deficits. This is reflected 
in the current results in Figure 9, which shows a trend for rats that were younger 
when administered MDMA to have higher 5-HT tissue levels two weeks later 
than rats that were older. This trend can be interpreted to mean that younger rats 
are less susceptible to the 5-HT deficits induced by MDMA pretreatment than are 
older rats. 
Further studies also reveal the difficulties in assessing 5-HT deficits in 
adolescent rats. Piper and Meyer (2004) found no significant long-term 
differences in SERT binding in Sprague-Dawley rats that received six 20 mg/kg 
MDMA injections between PD 35 and PD 60. This is a similar age distribution to 
the rats in the present study, although the dosing regime is considerably different. 
In addition, Marston et al. (1999) reported moderate significant 5-HT deficits in 
rats weighing 150-180g, 16 days following a MDMA regime of 90 mg/kg in total 
over three days. While this study is not directly comparable to the current 
experiments due to the considerable differences in MDMA dose and the use of 
Lister Hooded rats, it may imply that a significant deficit would have been seen in 
the current study with a considerably higher MDMA dose. It is also possible that 
5-HT deficits would have been evident in the current experiments at one week 
post MDMA pretreatment, as opposed to two weeks. Broening, Bacon and Slikker 
(Broening et al., 1994) found 5-HT deficits one week after a single 40 mg/kg 
MDMA injection in PND 40 rats. In summary it is evident that MDMA-induced 
5-HT deficits in adolescent rats are transient if detectable at all, and therefore rats 
of this developmental period are unlikely to exhibit 5-HT deficit-related changes 
in 5-HT1A autoreceptor sensitivity. The present experiments contribute to the body 
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of literature by providing further evidence of the effects of MDMA in adolescent 
rats. 
Ambient Temperature 
A further factor that may have contributed to the unsubstantial 5-HT deficits 
is the ambient temperature of the room in which rats were administered MDMA. 
A large body of findings demonstrate that the ambient temperature has a 
considerable impact on 5-HT deficits induced by MDMA (Schmidt, Black, 
Abbate, & Taylor, 1990; Miller & O’Callaghan, 1994; Farfel & Seiden, 1995; 
Dafters, 1995; Malberg & Seiden, 1998). The ambient temperature in the current 
experiments was controlled at 21°C, which as revealed by Malberg and Seiden, is 
not necessarily conducive to inducing 5-HT deficits. Malberg and Seiden reported 
that at temperatures of 20-24°C there were no deficits in 5-HT and 5-HIAA levels 
in the frontal cortex, striatum or hippocampus two weeks following MDMA (40 
mg/kg) administration in adult rats, with deficits only evident at temperatures 
above 24°C. The importance of ambient temperature is also seen in that some 
researchers use an increased temperature to encourage MDMA-induced deficits 
(2001). Conversely, there are reports of substantial MDMA-induced 5-HT deficits 
at ambient temperatures of approximately 22°C (Scanzello et al., 1993; Fischer et 
al., 1995). In summary, the evidence suggests that at between 20 and 24°C 5-HT 
deficits are more elusive than at higher temperatures. Therefore, the ambient 
temperature in the current experiments could have had a marked impact in 
preventing 5-HT deficits. 
Hypothermic Response 
Previous studies that have examined the influence of repeated MDMA 
exposure on the hypothermic response to 8-OH-DPAT found either no change 
(McNamara, Kelly, & Leonard, 1995; Granoff & Ashby, 2001; Mechan, O’Shea, 
Elliott, Colado, & Green, 2001) or a potentiation of the response (Aguirre et al., 
1998). The 8-OH-DPAT hypothermic response results in the current experiments 
are consistent with those that found no change. Potentiation of the hypothermic 
response, as found by Aguirre et al., would have been the expected result 
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consistent with the hypothesis of this study. However, there are a number of 
factors that make the 8-OH-DPAT hypothermic response difficult to use as a 
measure of 5-HT1A sensitivity. First, the exact method of action of the 
hypothermic response to 8-OH-DPAT remains a controversial issue. For instance, 
Aguirre et al. attributed the potentiation they found to changes in the postsynaptic 
5-HT1A heteroreceptors, as they took the position that 8-OH-DPAT's hypothermic 
response is postsynaptically mediated. Second, with systemic administration of 8-
OH-DPAT it is not possible to know the degree to which the drug is activating pre 
or postsynaptic 5-HT1A receptors and hence where the neuroadaptations occur. 
For instance, Aguirre et al. used a larger 1 mg/kg dose in comparison to the 
smaller, autoreceptor-selective doses used in the current experiments, and 
therefore potentially activated postsynaptic heteroreceptors. Third, 8-OH-DPAT 
has significant agonist activity at 5-HT7 receptors in addition to 5-HT1A receptors, 
and 5-HT7 receptors may be the most important for eliciting hypothermia within 
the dose range of 8-OH-DPAT used in the present study (Hedlund et al., 2004). 
Thus, the hypothermic effect of 8-OH-DPAT is complex and is likely to involve 
multiple receptor subtypes, which introduces confounding factors when 
attempting to selectively measure changes in 5-HT1A autoreceptor sensitivity. 
Methodological Issues and Stress 
Several further methodological issues in the current experiments are worth 
discussing. The hypothermic response measurement was performed using a rectal 
probe, which presents a number of challenges. The rats must be handled, 
sometimes at length, for accurate measurements to be recorded. This procedure 
can be highly stressful to the animal, and the associated synthesis-dependent 
increases in 5-HT levels caused by the stress response introduce more variability 
into the data (Joseph & Kennett, 1983; Adell, Casanovas, & Artigas, 1997). 
Another high stress procedure was administration of NSD-1015. Due to the 
concentration required of the drug it was mixed at 20 mg/ml and hence required a 
large volume of fluid to be injected, which took markedly longer than a typical i.p. 
injection. Furthermore, the solution often caused an adverse reaction in the rats 
for unknown reasons. Adell et al. reported that a subcutaneous injection of saline 
(1 mg/ml) caused 5-HT increases of up to 220% of baseline in the raphe nuclei, 
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and 160% of baseline in the amygdala, peaking at 30 minutes. Related to this, 
Joseph and Kennett revealed that such stress-induced 5-HT release is dependent 
on an increase in 5-HT synthesis, and hence should affect tissue level 
measurements. Therefore, it was likely that the handling required for temperature 
measurements and the additional stress response of the NSD-1015 administration 
introduced a considerable degree of variability in the 5-HT measurements. 
Alternative Hypotheses 
Irrespective of the lack of 5-HT deficits, the possibility exists that the 5-
HT1A autoreceptor does not become supersensitised following MDMA 
pretreatment, and hence no significant variation in 8-OH-DPAT effect would be 
expected in MDMA pretreated rats. MDMA-induced impairments could result 
from neuroadaptations to another component of the 5-HT system. For instance, 
changes in sensitivity of the postsynaptic 5-HT1A heteroreceptor may contribute to 
MDMA-induced impairments. The 5-HT1A heteroreceptors regulate, usually 
negatively, the activity of non-serotonergic neurons in 5-HT terminal areas by 
coupling to inhibitory G proteins (Gi/o) and inhibiting adenylate cyclase (De Vivo 
& Maayani, 1986; Sprouse & Aghajanian, 1988). As a consequence, changes in 5-
HT1A heteroreceptors can cause lasting changes in protein expression and cellular 
activity. Furthermore, while 5-HT1A autoreceptors primarily control serotonergic 
neuronal firing, 5-HT1A heteroreceptors may also play a role in the regulation of 
firing rate and serotonin release of 5-HT neurons through neuronal feedback loops 
between projection areas and raphe nuclei (Ceci, Baschirotto, & Borsini, 1994; 
Bosker, Klompmakers, & Westenberg, 1997; Hajós, Hajós-Korcsok, & Sharp, 
1999; Celada, Puig, Casanovas, Guillazo, & Artigas, 2001). In this way, it is 
possible that neuroadaptations in postsynaptic 5-HT1A heteroreceptors could have 
a direct impact on 5-HT transmission, and hence be a potential cause of 5-HT-
related impairments induced by MDMA. Evidence for this argument comes from 
a study in which repeated MDMA exposure caused an increase in 5-HT1A 
heteroreceptor binding in the frontal cortex 7 days later (Aguirre, Galbete, 
Lasheras, & Del Río, 1995). The authors note that this change would make sense 
in terms of adaptive changes to compensate for reduced functioning of the 5-HT 
system. 
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5-HT1A Desensitisation 
A further alternative hypothesis is that MDMA impairments stem from a 
desensitisation of the 5-HT1A autoreceptor, as opposed to a supersensitisation. 
Aguirre, Galbete, Lasheras and Del Rio (1995) also reported a reduction in 5-
HT1A binding in the brain stem area incorporating the raphe nuclei, and argued 
that this MDMA-induced desensitisation of 5-HT1A autoreceptors may be due to a 
compensatory mechanism in response to the putative loss of 5-HT nerve terminals. 
In the current experiments, possible evidence of desensitisation of the 5-HT1A 
autoreceptor is seen in Figure 5, which shows that there was a nonsignificant 
trend in the MDMA pretreated rats of an attenuated 8-OH-DPAT hypothermic 
response. This is consistent with the argument of Aguirre et al. (1998) that 
MDMA induces down-regulation of presynaptic 5-HT1A autoreceptors. However, 
as previously discussed, the hypothermic response measurement is problematic. 
Desensitisation of the 5-HT1A autoreceptor may be an expected response to 
MDMA for a number of reasons. MDMA functions in part by dramatically 
increasing available 5-HT that, in the raphe nuclei, acts as an agonist to 5-HT1A 
autoreceptors. In this sense, MDMA indirectly acts like the 5-HT1A agonist 8-OH-
DPAT, which has been shown to cause internalisation of 5-HT1A autoreceptors in 
the DRN 15 minutes after systemic administration (0.5 mg/kg i.v.) (Riad, Watkins, 
Doucet, Hamon, & Descarries, 2001). It is also established that long term 
activation of the 5-HT1A autoreceptor leads to desensitisation through an 
internalisation of the receptor (Kreiss & Lucki, 1997; Dong, De Montigny, & 
Blier, 1997; Blier, Pineyro, El Mansari, Bergeron, & De Montigny, 1998; Blier & 
De Montigny, 1998; Riad et al., 2000; Assié, Lomenech, Ravailhe, Faucillon, & 
Newman-Tancredi, 2006). Moreover, selective serotonin reuptake inhibitors 
(SSRIs), which act in part similar to MDMA in terms of increasing available 5-
HT, eventually cause desensitisation of 5-HT1A autoreceptors (Blier & De 
Montigny, 1998; Le Poul et al., 2000). Additionally, reductions in the SERT 
protein in the raphe nuclei via gene transfer have been shown to cause a 
desensitisation of 5-HT1A receptors, as determined by a decrease in 5-HT1A 
receptor-stimulated [35S]GTP-γ-S binding (Fabre et al., 2000). MDMA also causes 
reductions in SERT expression (Battaglia et al., 1988; Scanzello et al., 1993; 
O’Shea et al., 2006). With respect to these points, it would make sense for 
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MDMA to cause a desensitisation of the 5-HT1A autoreceptor, as opposed to the 
hypothesised supersensitisation. 
An important consideration with the desensitisation hypothesis is that a 
desensitised 5-HT1A autoreceptor does not align well with the cognitive and mood 
impairments associated with MDMA abuse. Desensitisation of the autoreceptor 
would enhance serotonergic neurotransmission – an outcome typically associated 
with wellbeing and an important method of action of SSRIs. Moreover, MDMA 
has many effects in addition to causing 5-HT release and potentially desensitising 
autoreceptors, and hence cannot be characterised solely in this way. In fact, the 5-
HT deficits caused by MDMA are likely to be due to other factors beyond the 
dramatic increase in 5-HT (Baumann, Ayestas, Dersch, & Rothman, 2001). 
Therefore, while there is a case for desensitisation of 5-HT1A autoreceptors with 
respect to one aspect of MDMA pharmacodynamics, it is unlikely to be at the root 
of 5-HT deficits induced by MDMA. Additionally, although it is possible that 5-
HT1A autoreceptor desensitisation and 5-HT deficits could occur independently, it 
would seem unlikely that such an instrumental regulatory component of the 5-HT 
system is not involved in the deficits and consequent functional impairments of 
MDMA abuse. 
Future Research 
There is a large degree of equivocacy in the MDMA studies investigating 5-
HT1A functioning, which is also reflected in studies that consider 5-HT1A 
functioning with other psychostimulants. For instance, with respect to binding 
studies, experiments with the effects of other psychostimulants on 5-HT1A binding 
report a complex mix of up and down receptor regulation, which are difficult to 
replicate and show no clear picture overall (Müller, Carey, Huston, & De Souza 
Silva, 2007). For these reasons, Müller et al. suggest that the 5-HT1A receptor may 
not be a good candidate to explain long-term impairments caused by 
psychostimulants such as MDMA. However, the theoretical basis behind MDMA-
induced sensitivity changes in the 5-HT1A autoreceptor is sound and it is too early 
to draw any reliable conclusions until the shortcomings of the present experiments 
are overcome by future research. Furthermore, even if an increase in autoreceptor 
sensitivity is not ultimately the central explanatory factor, there is considerable 
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theoretical support and evidence for other neuroadaptive changes in the 5-HT1A 
receptor system that are likely to provide a source of valuable future research. 
There are a number of possibilities for future research to overcome the 
shortcomings of the current experiments. First, adult rats with a more tightly 
restricted weight range should be used. It is evident that long-term MDMA-
induced 5-HT deficits are highly variable or non-existent in adolescent rats, 
potentially due to their still developing 5-HT system. The use of adult rats would 
ensure more marked and consistent 5-HT deficits and hence allow the 
investigation of sensitivity changes in the 5-HT1A autoreceptor that may form part 
of these deficits. Second, the ambient temperature during MDMA administration 
should be maintained at a higher temperature, at least over 24°C, to ensure 
significant 5-HT deficits. Moreover, a higher ambient temperature above 21°C is 
closer to temperatures experienced by human MDMA users in a typical club 
environment (Schifano, 2004) and hence provides more ecological validity. Third, 
higher doses of MDMA, or a dosing regime that extends over multiple days, could 
be used to produce more marked 5-HT deficits. More profound deficits may be 
required to see changes in 5-HT1A autoreceptors. Fourth, the use of other 
behavioural methods for investigating 5-HT1A autoreceptor state may assist in 
detecting sensitivity changes. For example, lower lip retraction is a behavioural 
measure of 5-HT1A autoreceptor activation (Berendsen, Jenck, & Broekkamp, 
1989; Moore, Rees, Sanger, & Perrett, 1993) and hence could be used as a 
correlate measure for changes in receptor sensitivity. 
With respect to the aforementioned points, the first step in the future would 
be to repeat Experiment 2 with adult rats, and a consistent ambient temperature of 
25°C during MDMA administration. This should produce reliable 5-HT deficits 
and consequently allow valid investigation of changes in 5-HT1A autoreceptor 
sensitivity. The addition of an alternative behavioural measure of 5-HT1A 
sensitivity, such as lower lip retraction, would provide greater evidence that the 5-
HT1A autoreceptor is implicated. If this next experiment fails to find any 5-HTP or 
behavioural differences in the MDMA pretreated group, then further experiments 
could be performed with higher doses of MDMA over multiple days. If either of 
these experiments are successful at finding changes in 5-HTP accumulation or 
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behavioural measures that would imply sensitivity changes of 5-HT1A 
autoreceptors, then the next step would be to more firmly establish these findings 
through binding studies, electrophysiological methods and more valid animal 
models of substance abuse and addiction. 
Ultimately, to show changes in sensitivity, a number of further studies 
would be required. Binding measurements of 5-HT1A agonists in the raphe nuclei 
at multiple time points after repeated MDMA exposure may provide further 
evidence of sensitivity changes. Additionally, histological analysis of receptors to 
investigate their location in the cell post MDMA exposure could provide evidence 
of the mechanisms of sensitivity changes, such as if receptor internalisation 
occurs. Finally, using in vivo electrophysiological methods it would be possible to 
examine the responses of individual 5-HT neurons in the rat raphe nuclei to 5-
HT1A receptor activation following MDMA pretreatment, to determine directly 
changes in sensitivity via firing rate properties. 
A further important future step in the research of 5-HT1A functioning and 
involvement in MDMA-induced impairments is using animals that have 
established addiction-related behaviour, such as those self-administering MDMA. 
The self-administration paradigm is a far superior approximation of human drug 
taking behaviour, and hence of the resulting deficits. While MDMA self-
administration has been well established (Schenk, Gittings, Johnstone, & Daniela, 
2003; Schenk et al., 2007; Schenk, 2009), at present there are no studies available 
that have measured 5-HT1A sensitivity changes due to prolonged MDMA 
exposure in a self-administration paradigm. 
Summary 
The current experiments did not find evidence to support the hypothesis that 
high-dose, repeated MDMA exposure leads to an increase in sensitisation of the 
5-HT1A autoreceptor. This was shown through an inability of autoreceptor-
selective doses of 8-OH-DPAT to produce sensitised 5-HTP accumulation and a 
sensitised hypothermic response. Therefore, the results of the current experiments 
would suggest that 5-HT1A supersensitisation does not result from MDMA abuse 
and hence is not a cause of the related cognitive and mood impairments. However, 
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there were a number of critical methodological issues with the current 
experiments, the most important being the age of the rats tested. The use of rats in 
their adolescence, potentially coupled with other factors such as a relatively low 
ambient temperature, was highly likely to prevent the formation of MDMA-
induced 5-HT deficits. As these deficits are indicative of a compromised 5-HT 
system, without their presence there is little basis on which to investigate 
neuroadaptations in the 5-HT1A autoreceptor.  
The current experiments contribute additional evidence of the nature of 
MDMA-induced 5-HT deficits in adolescent rats, and also further insight into the 
mechanisms of action of NSD-1015 and 8-OH-DPAT in the 5-HT system of 
adolescent rats. It is hoped that future research will overcome the shortcomings of 
the current experiments and contribute further valuable findings to the body of 
MDMA knowledge. 
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